- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00396201
AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease
Treatment With AMD3100 Added to a Mobilizing Regimen of G-CSF to Increase the Number of Peripheral Blood Stem Cells in Patients With Hodgkin's Disease
Study Overview
Detailed Description
Participants with HD who have been treated with cyto-reductive chemotherapy, who are to undergo autologous stem cell transplantation, and who meet the inclusion/exclusion criteria are eligible to enter this study. The only changes to the standard of care is the addition of plerixafor to a G-CSF mobilization regimen on the day prior to apheresis and the collection of blood samples for pharmacokinetic (PK) analysis and pharmacodynamics (PD) analysis by CD34+ fluorescence-activated cell sorting (FACS) analysis. Blood samples for PK and CD34+ FACS analyses will be obtained prior to and after the first dose of plerixafor. Participants will undergo mobilization with G-CSF (10 µg/kg daily) and will receive plerixafor (240 µg/kg) on each day prior to apheresis. Participants will be apheresed for up to 5 consecutive days in order to collect the target number of CD34+ stem cells, (≥5*10^6 cells/kg). After apheresis, all participants will be treated with high dose chemotherapy in preparation for transplantation. Participants will be transplanted with cells obtained from the G-CSF plus plerixafor mobilization regimen. In the event that a sufficient number of cells for transplantation are not obtained from the collection, cells may be retained and pooled for transplantation at the investigator's discretion.
The primary endpoint is the proportion of HD participants who collect ≥5*10^6 CD34+ cells/kg with this mobilization regimen. The secondary endpoints include the safety of this mobilization regimen, the proportion of participants who collect ≥2*10^6 CD34+ cells/kg, the change in CD34+ cells circulating in the peripheral blood after a dose of plerixafor, and the number of days of apheresis required to obtain ≥5*10^6 CD34+ cells/kg. In addition, success of the transplantation will be evaluated by measuring the time to engraftment of PMNs and PLTs. Participants will be followed for 12 months to assess transplant durability.
This study was previously posted by AnorMED, Inc. In November 2006, AnorMED, Inc. was acquired by Genzyme Corporation. Genzyme Corporation is the sponsor of the trial.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Missouri
-
St Louis, Missouri, United States, 63110-1093
- Washington University School of Medicine,Division of Bone Marrow Transplantation & Leukemia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of HD eligible for autologous transplantation
- No more than 3 prior regimens of chemotherapy (Rituximab is not considered chemotherapy for the purpose of this study.)
- 4 weeks since last cycle of chemotherapy
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- The patient has recovered from all acute toxic effects of prior chemotherapy
- White blood cell count (WBC) >3.0*10^9/L
- Absolute polymorphonuclear cells (PMN) count >1.5*10^9/L
- Platelet (PLT) count >100*10^9/L
- Serum creatinine ≤2.2 mg/DL
- Serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT) and total bilirubin <2 x upper limit of normal (ULN)
- Left ventricle ejection fraction >45% by normal echocardiogram or multiple-gated acquisition (MUGA) scan
- Forced expiratory volume of the lung in the first second (FEV1) >60% of predicted or diffusing capacity of the lung for carbon monoxide (DLCO) >45% of predicted
- Negative for human immunodeficiency virus (HIV)
Exclusion Criteria:
- A co-morbid condition which, in the view of the investigator, renders the patient at high risk for treatment complications
- Patients who have failed previous collections
- A residual acute medical condition resulting from prior chemotherapy
- Hodgkin's disease involving the central nervous system
- Acute infection
- Fever (temp >38°C/100.4°F)
- Patients whose actual body weight exceeds 150% of their ideal body weight
- History of ventricular arrhythmias
- History of paresthesias
- Patients who previously received experimental therapy within 4 weeks of enrolling in this study or who are currently enrolled in another experimental study during the mobilization period
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Participants with Hodgkin's Disease (HD)
Participants with Hodgkin's Disease who were eligible for autologous peripheral blood stem cell transplantation.
|
Randomized participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection.
On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection.
On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF).
Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 4 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Participants Who Achieved ≥5*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF
Time Frame: Day 5 up to Day 9
|
The proportion of total participants who mobilized ≥5*10^6 CD34+ cells/kg based on data from local laboratories.
|
Day 5 up to Day 9
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Participant Counts of Adverse Events During the Treatment Period
Time Frame: Day 0 - approximately day 38
|
Adverse Events were graded by the investigator using the World Health Organization (WHO) Adverse Event Grading Scale and were assessed for severity (mild, moderate, severe and life-threatening) and relatedness (5 steps from 'not related' to 'definitely related') to study treatment. Time frame starts on the first day of G-CSF mobilization to the day prior to chemotherapy/ablative treatment in preparation for transplant. See the separate Serious Adverse Event section for a summary of AEs the investigator assessed as serious. |
Day 0 - approximately day 38
|
Proportion of Participants Who Achieved ≥2*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF
Time Frame: Day 5 up to day 9
|
The proportion of total participants who mobilized ≥2*10^6 CD34+ cells/kg based on data from local laboratories.
|
Day 5 up to day 9
|
Fold (Relative) Increase in Peripheral Blood (PB) CD34+ Cells/µL
Time Frame: Days 4-5 (first dose of plerixafor to apheresis)
|
The fold increase was measured by fluorescence activated cell sorting (FACS) analysis using local laboratory data and was expressed as a ratio.
Fold increase = (pre-apheresis PB CD34+ cells/µL)/(pre-plerixafor dosing PB CD34+ cells/µL).
|
Days 4-5 (first dose of plerixafor to apheresis)
|
Participant Counts Grouped by Number of Apheresis Days Required to Collect ≥ 5*10^6 CD34+ Cells/kg
Time Frame: Day 5 up to day 9
|
Counts of participants grouped by the number of apheresis days needed to collect a target for transplantation of ≥5*10^6 CD34+ cells/kg as determined by local laboratory data.
|
Day 5 up to day 9
|
Number of Days Post-Transplantation to Polymorphonuclear Leukocyte (PMN) Engraftment
Time Frame: Up to Month 13 (up to 12 months post transplant)
|
Median number of days to PMN engraftment following transplantation.
Engraftment was defined as PMN counts ≥ 0.5*10^9/L for 3 consecutive days or ≥ 1.0*10^9/L for 1 day.
Time to engraftment corresponded to the first day that the criteria were met.
|
Up to Month 13 (up to 12 months post transplant)
|
Number of Days Post Transplantation to Platelet (PLT) Engraftment
Time Frame: Up to Month 13 (up to 12 months post transplant)
|
Median number of days to PLT engraftment following transplantation.
Engraftment success was evaluated according to local site practice.
Time to engraftment corresponded to the first day that criteria were met.
|
Up to Month 13 (up to 12 months post transplant)
|
Number of Participants With a Durable Graft at 12 Months
Time Frame: 13 months
|
Graft durability was assessed by the Investigator based on complete blood count (CBC) and differential analyses at 12 months post transplantation.
A graft was considered durable if blood counts were normal (acceptable) and still met the criteria for PLT and PMN engraftment.
|
13 months
|
Maximum Plasma Concentration (Cmax) Following a Single Dose of Plerixafor
Time Frame: Day 4
|
Maximum plasma concentration (Cmax) of plerixafor following the first single dose of 240 ug/kg plerixafor administered.
|
Day 4
|
Time to Maximum Plasma Concentration (Tmax) Following a Single Dose of Plerixafor
Time Frame: Day 4
|
Time to maximum plasma concentration (Tmax) of plerixafor following the first single dose of 240 ug/kg plerixafor was determined from direct observation of the data.
|
Day 4
|
Half-life (T1/2) Following a Single Dose of Plerixafor
Time Frame: Day 4
|
Plasma elimination half-life (T1/2) following a single dose of 240 ug/kg plerixafor.
|
Day 4
|
Area Under the Plasma Concentration-time Curve From 0 to 10 Hours (AUC0-10) Following a Single Dose of Plerixafor
Time Frame: Days 4-5
|
Area under the plasma concentration-time curve from 0 to 10 hours (AUC0-10) following the first single dose of 240 ug/kg plerixafor.
|
Days 4-5
|
Apparent Clearance (CL/F) of Single-dose Plerixafor
Time Frame: Day 4-5
|
Apparent clearance was calculated the mean dose of plerixafor divided by the area under the plasma concentration-time curve from 0 hours to infinity (AUC0-inf).
|
Day 4-5
|
Apparent Volume of Distribution (Vz/F) Following a Single-dose of Plerixafor
Time Frame: Day 4
|
The volume of distribution (Vz/F) was calculated as apparent clearance divided by the terminal elimination rate constant.
|
Day 4
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AMD3100-2106
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hodgkin's Disease
-
University Hospital, BrestCompletedDiagnostic Imaging | Relapsed Non Hodgkin Lymphoma | Relapsed Hodgkin's Disease, Adult | Malignant Lymphoma
-
Stanford UniversityNational Institute of Allergy and Infectious Diseases (NIAID); National Institutes...CompletedLymphoma | Hodgkin's Lymphoma | Hodgkin DiseaseUnited States
-
Hospital JP GarrahanHospital Pereyra Rosell, Montevideo, UruguayRecruitingPediatric Hodgkin's DiseaseArgentina
-
Bayside HealthCompletedNon-Hodgkin's Lymphoma | Hodgkin's DiseaseAustralia
-
Bayside HealthCompletedNon-Hodgkin's Lymphoma | Hodgkin's DiseaseAustralia
-
National Cancer Institute (NCI)CompletedNon Hodgkin's Lymphoma | Hodgkin's DiseaseUnited States
-
Dana-Farber Cancer InstituteBeth Israel Deaconess Medical Center; Brigham and Women's Hospital; MedImmune...CompletedLymphoma | Non-Hodgkin's Lymphoma | Hodgkin's DiseaseUnited States
-
Baylor College of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH); The Methodist... and other collaboratorsRecruitingLymphoma | Non-Hodgkin's Lymphoma | Hodgkin's Disease | Lymphoproliferative DiseaseUnited States
-
Genzyme, a Sanofi CompanyCompletedTransplantation | Lymphoma (Non-Hodgkin's Lymphoma) | Hodgkin's Disease or Multiple Myeloma | Front Line MobilizationNetherlands, France, Germany, Sweden, Spain, Italy, United Kingdom
-
University Health Network, TorontoCompletedHodgkin's Lymphoma | Non Hodgkin's LymphomaCanada
Clinical Trials on G-CSF Plus Plerixafor
-
Genzyme, a Sanofi CompanyAnorMEDCompletedLymphoma, Non-Hodgkin | Multiple MyelomaGermany
-
Genzyme, a Sanofi CompanyCompletedLymphoma, Non-Hodgkin | Multiple MyelomaCanada
-
Genzyme, a Sanofi CompanyTerminatedMultiple Myeloma | Lymphoma, Non-Hodgkin'sUnited States
-
Duke UniversityGenzyme, a Sanofi CompanyCompletedMultiple Myeloma | Non-Hodgkins Lymphoma | Hodgkins DiseaseUnited States
-
Genzyme, a Sanofi CompanyAnorMEDCompletedLymphoma, Non-Hodgkin | Multiple MyelomaUnited States
-
Genzyme, a Sanofi CompanyCompletedAutologous Stem Cell TransplantationUnited States
-
SanofiCompletedAutologous Haematopoietic Stem Cell TransplantChina
-
Stephen CoubanGenzyme, a Sanofi CompanyCompletedMalignant Lymphoma, Stem Cell TypeCanada
-
Genzyme, a Sanofi CompanyApproved for marketing